Formycon

Formycon is a German, publicly traded biosimilar developer with a commercial-stage product and a robust pipeline targeting high-value biologic drugs. The company leverages deep scientific and regulatory expertise to develop biosimilars for markets like the EU and US, aiming to capture significant value in the growing biosimilars market. Its strategy focuses on complex molecules in ophthalmology and immunology, with recent progress including a key settlement for its aflibercept biosimilar in Europe.

Integrated expertise in biosimilar development, encompassing protein analytics, process development, clinical trial design, and regulatory pathways for global markets.

Formycon competes with other pure-play biosimilar developers (e.g., Bio-Thera, Coherus BioSciences) and the biosimilar divisions of large generic and pharmaceutical companies (e.g., Sandoz (Novartis), Viatris, Amgen, Samsung Bioepis). Competition is intense on development speed, patent challenges, manufacturing cost, and commercial execution. Formycon differentiates through its focused expertise and proven track record in development.